34° Mostly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.040 +0.030 (+2.97%)

Streaming Delayed Price Updated: 1:14 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

7 Cathie Wood Stocks Trading at a Discount Right Now ↗

July 26, 2022

These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments.

Via InvestorPlace

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock ↗

July 12, 2022

Via Benzinga

Expert Ratings for Fate Therapeutics ↗

July 11, 2022

Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:

Via Benzinga

7 Small-Cap Stocks to Buy in July 2022 ↗

July 04, 2022

These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.

Via InvestorPlace

Recap: Fate Therapeutics Q1 Earnings ↗

May 04, 2022

Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗

July 12, 2022

Upgrades

Via Benzinga

Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗

June 14, 2022

Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022 ↗

July 11, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

What 4 Analyst Ratings Have To Say About Fate Therapeutics ↗

March 04, 2022

Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Fate Therapeutics: Q4 Earnings Insights ↗

February 28, 2022

Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Fate Therapeutics's Earnings: A Preview ↗

February 25, 2022

Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Earnings Outlook For Fate Therapeutics ↗

February 25, 2022

Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch ↗

February 08, 2022

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...

Via Benzinga

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗

January 14, 2022

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...

Via Benzinga

Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today ↗

January 05, 2022

Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 ↗

December 15, 2021

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

December 15, 2021

Barclays boosted the price target on Sysco Corporation (NYSE:

Via Benzinga

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗

December 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...

Via Benzinga

Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma ↗

December 14, 2021

Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the...

Via Benzinga

Hedge Funds Are Selling Vontier Corporation ↗

December 11, 2021

Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

Cathie Wood Likes Fate Therapeutics, Should You? ↗

December 01, 2021

The biotech has an interesting pipeline, but it's all early stage products.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗

November 09, 2021

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:

Via Benzinga

Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

FATE earnings call for the period ending October 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

All News about Fate Therapeutics, Inc. - Common Stock

Sections

Services